Gilead’s tablet for unsuccessfully treated patients with other HCV drugs cleared in USA

The U.S. Food and Drug Administration on Tuesday approved Gildad’s Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir.

Read more

FDA approves first generic of drug for prevention of HIV and to treat HIV-1

The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.

Read more